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Abstract: Chronic spontaneous urticaria (CSU) is a disease with significant morbidity and 
relative prevalence that has important effects on the quality of life (QoL) of those who suffer 
from it. Omalizumab is a recombinant humanized anti-immunoglobulin E (IgE) antibody that 
binds to the Cε3 domain of the IgE heavy chain and prevents it from binding to its high-affinity 
receptor FcεRI. It has been largely studied in the field of asthma and is currently approved for 
the treatment of both adult and pediatric (children; .6-year-old) patients. In addition, in recent, 
well-controlled clinical trials in patients with CSU resistant to antihistamines, add-on therapy 
with subcutaneous omalizumab significantly reduced the severity of itching, and the number 
and size of hives, and increased patients’ health-related QoL and the proportion of days free 
from angioedema compared with placebo, with an excellent tolerance. Thus, omalizumab is an 
effective and well-tolerated add-on therapy for patients with CSU who are symptomatic despite 
background therapy with H1 antihistamines. In this review, we cover the following points: 
epidemiology, pathogenesis, assessment of activity, impact on QoL, and treatment of CSU, and 
finally, we focus on omalizumab in the treatment of CSU including the pharmacokinetic proper-
ties and mechanism of action, and use in pregnant women, nursing infants, and children.
Keywords: omalizumab, chronic spontaneous urticaria, antihistamines, subcutaneous admin-
istration, add-on therapy
Introduction
Urticaria is a disease characterized by the development of wheals (hives) or angioedema, 
or both, with associated intense pruritus. Individual lesions last less than 24 hours with 
the skin returning to its normal appearance, usually within 1–24 hours. Most episodes 
last less than 6 weeks and are diagnosed as acute urticaria; chronic urticaria (CU) is 
defined as wheals or angioedema, or both, occurring intermittently or continuously 
for at least 6 weeks. This disease has a major impact on the quality of life (QoL) of 
those patients affected with an effect on both objective functioning and subjective 
well-being. CU has been further classified into different subtypes: spontaneous and 
inducible by physical stimuli (Table 1). The terms chronic spontaneous urticaria 
(CSU) and chronic idiopathic urticaria (CIU) are used interchangeably in the scientific 
papers. The joint initiative of the Dermatology Section of the European Academy of 
Allergy and Clinical Immunology (EAACI), the EU-funded network of excellence, the 
Global Allergy and Asthma European Network (GA2LEN), the European Dermatology 
Forum (EDF), and the World Allergy Organization (WAO) in the EAACI/GA2LEN/
EDF/WAO guideline published in 2014, as well as the British Society for Allergy 
and Clinical Immunology (BSACI) guideline for the management of CU prefers the 
use of the term CSU because it implies an underlying endogenous cause.1,2 The Joint 
Task Force on Practice Parameters (JTFPP), representing the American Academy 
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of Allergy, Asthma and Immunology, the American Col-
lege of Allergy, Asthma and Immunology, and the Joint 
Council of Allergy, Asthma and Immunology still continue 
to use CIU.3
Omalizumab is a recombinant humanized anti- 
immunoglobulin E (IgE) antibody that binds to the Cε3 
domain of the IgE heavy chain. It has been largely studied 
in the field of asthma and is currently approved for the treat-
ment of both adult and pediatric (children; .6-year-old) 
patients. The presence of IgG anti-alpha subunit of the IgE 
receptor has been demonstrated in a portion of patients with 
CSU.4 The rationale to employ omalizumab for controlling 
CSU was that the IgE binding with omalizumab causes 
internalization of the IgE receptor, and as a consequence, 
the disappearance of the autoantigen. However, omalizumab 
might have additional effects, since it is also effective in 
non-autoimmune urticaria.5
Epidemiology of CSU
The prevalence of CSU is unknown, but it is estimated to 
be 0.5%–1% of the population, and the annual incidence is 
estimated at 1.4%.1,3
In 2004, Gaig et al conducted a population-based study 
among adults in Spain to approach the real prevalence of CU.6 
They found a prevalence of 0.6% with a predominance of 
CU in women (odds ratio =3.82) and reported that approxi-
mately 80% of patients were symptom-free after 1 year, and 
symptoms last from 1 year to 5 years in 8.7% and for more 
than 5 years in 11.3%.6
Pathogenesis of CSU
While the pathogenesis of CSU has been extensively 
investigated, no theory has been conclusively proven, and a 
combination of mechanisms may play a role.
Vasoactive mediators released from mast cells and baso-
phils play a key role in the pathogenesis of CSU. Despite 
the presence of other mediators (eicosanoids, cytokines, 
and proteases), histamine is the most prominent and acts 
on H1 receptors (85%) and H2 receptors (15%) in the skin. 
While histamine binding to H1 receptors leads to pruritus 
(by stimulation of C fibers), binding to receptors on post-
capillary venules induces vasodilation, increased vascular 
permeability, and edema.7
Mechanisms other than histamine release have been 
implicated in CSU and include abnormalities in basophil 
signal transduction and number, and autoimmunity. Intrad-
ermal injection of autologous plasma and/or sera from some 
patients with CSU causes a wheal and flare reaction; this 
test is named autologous serum skin test and could reflect 
the presence of histamine-releasing autoantibodies. Differ-
ent autoantibodies can be found in up to 45% of patients 
with CSU. These autoantibodies can be targeted at the IgE 
(Fc portion), the high-affinity IgE receptor (FcεRI), and also 
the antithyroid autoantibodies (both anti-microsomal and 
anti-thyroperoxidase).8
There is also increasing evidence of altered number, 
structure, function of basophils, and defects in their traffick-
ing. Basopenia is well documented, and basophil numbers 
are inversely related to urticaria severity.9 Numerical and 
behavioral alterations in basophils complemented by changes 
in signaling molecule expression and function as well as 
aberrant activation of extrinsic pathway of coagulation are 
other alternative hypotheses.10
Assessment of activity of CSU  
and impact on QoL
Disease activity in CSU may be assessed with the “Urticaria 
Activity Score” during 7 days (UAS7) (Table 2). This tool 
is a unified and simple scoring system that was proposed in 
the last version of the guidelines and has been validated in 
many languages.11 For patients with associated angioedema, 
a novel activity score, the Angioedema Activity Score, has 
been developed and validated by the group of Professor 
Maurer in Berlin.12 It is important, in addition to disease 
Table 1 Chronic urticaria subtypes
Spontaneous Inducible (physical urticaria)
Chronic spontaneous urticaria Urticaria factitia, dermographic urticaria








Table 2 Urticaria Activity Score 7 (UAS7): a validated tool with 
which to follow disease activity in clinical practice
Score Wheals Pruritus
0 None None
1 Mild (,20  
wheals/24 hours)
Mild (present but not annoying or  
troublesome)
2 Moderate (20–50  
wheals/24 hours)
Moderate (troublesome but does  
not interfere with normal daily  
activity or sleep)
3 Intense (.50  
wheals/24 hours)
Intense (severe pruritus, which is  
sufficiently troublesome to interfere 
with normal daily activity or sleep)
Note: Sum of score: 0–6 for each day is summarized over 1 week (maximum 42).





activity, to assess the impact of disease on QoL of urticaria 
patients both in clinical care and in trials. Although specific 
dermatological skin disease questionnaires have been used 
in CU, a specific questionnaire, the CU-Q2oL, was designed 
in 200513 consisting of 23 questions or items grouped into six 
QoL categories associated with the disease: itch (two ques-
tions), swelling (two questions), impact on daily activities 
(six questions), sleep problems (five questions), limitations 
(three questions), and looks (five questions). It has been 
shown to be reproducible and sensitive to change, and has 
been validated in several language versions.14 Recently, 
attempts have been made to combine these evaluations to 
create a specific tool that would enable us to simultane-
ously evaluate the severity of the condition and the impact 
of symptoms on QoL. One such tool is the Urticaria Control 
Test (UCT). This tool has four items, and each item has five 
answer options (scored with 0–4 points). Low points indicate 
high disease activity and low disease control. Accordingly, 
the minimum and maximum UCT scores are 0 and 16, 
respectively, with 16 points indicating complete disease 
control. This tool also allows us to compare global changes 
brought about by different treatments.15 It would be of inter-
est in the future to explore the utility of other disease score 
dermatology tools as Chromameter, DermaSpectrometer, or 
Skin-Visiometer® for CSU.
Treatment of CU
Recent guidelines, EAACI/GA2LEN/EDF/WAO,1 JTFPP,3 
and BSACI,2 recommend a step-by-step approach to the 
management of CSU (Table 3). Disease activity and QoL 
should be properly assessed in every stage. Identification and 
elimination or avoidance of the triggers stimulus or aggravat-
ing factors of the CSU should also be performed. First-line 
pharmacotherapy in CSU consists of modern nonsedating, 
second-generation H1 antihistamines.1–3 H2 antihistamines 
may also be used in addition to the first-generation antihis-
tamines. Sedating, first-generation H1 antihistamines which 
have been used during years in clinical practice for CSU are 
considered at bed time as a second-line addition and only 
in the American guideline.3 Sedating, first-generation H1 
antihistamines are excluded in the European guidelines.1,2 All 
guidelines recommend dose escalation (up to fourfold) of the 
chosen antihistamine as a second-line option, although the 
British and American guidelines also recommend adding a 
second antihistamine. Omalizumab is considered a third-line 
treatment option in the European guidelines.1,2 The American 
guideline includes omalizumab as a fourth-line option, stress-
ing that the benefits need to be weighed against the cost 
burden.3 Omalizumab has been approved in March 2014 by 
the US Food and Drug Administration (FDA) and by Euro-
pean Medicines Agency (EMA) and in August 2014 by Heath 
Canada for use in adults and children aged 12 years and above 
with CSU refractory to H1 antihistamines.16,17 The approval 
of omalizumab for this indication is based on the results 
published from two cardinal Phase III clinical trials known 
as ASTERIA II and GLACIAL. A third Phase III clinical trial 
named ASTERIA I also shows the same efficacy.18–20
Omalizumab in the treatment  
of CSU
Omalizumab is a recombinant humanized anti-IgE antibody 
that binds to the Cε3 domain of the IgE heavy chain where IgE 
Table 3 Recommended pharmacotherapy algorithms for chronic spontaneous urticaria (or chronic idiopathic urticaria)
EAACI/GA2LEN/EDF/WAO1 JTFPP3 BSACI2
First line: modern second-generation 
antihistamines
Step 1: second-generation antihistamines Step 1: second-generation 
antihistamines
Second line: increase second-generation 
antihistamine dosage up to fourfold
Step 2: one or more of the following: 
dose advancement of second-generation 
antihistamine, add another second-
generation antihistamine, add H2 antagonist, 
add leukotriene receptor antagonist, or add 
first-generation antihistamine at bedtime
Step 2: increase second-generation 
antihistamine dosage up to fourfold 
or add a second antihistamine
Third line: add omalizumab or 
ciclosporin A or montelukast
Step 3: dose advancement of potent 
antihistamine (eg, hydroxyzine or doxepin) 
as tolerated
Step 3: consider an anti-leukotriene 
agent
Step 4: add alternative agent: omalizumab 
or cyclosporine, other anti-inflammatory 
agents, immunosuppressants, or biologics
Step 4: consider an immunomodulant 
(eg, omalizumab, cyclosporine)
Short course (up to 10 days) of 
corticosteroids may be used for 
exacerbations as needed
A short course of corticosteroids 
may be appropriate in severe 
episodes at any stage
Abbreviations: EAACI, European Academy of Allergy and Clinical Immunology; GA2LEN, Global Allergy and Asthma European Network; EDF, European Dermatology 
Forum; WAO, World Allergy Organization; JTFPP, Joint Task Force on Practice Parameters; BSACI, British Society for Allergy and Clinical Immunology.





binds to its high-affinity receptor FcεRI. It has been largely 
studied in the field of asthma and is currently approved for the 
treatment of both adult and pediatric (children; .6-year-old) 
patients with moderate-to-severe asthma.21–23
The original evidence of efficacy of omalizumab in 
CSU stemmed from several case series or small trials.5,24–28 
Although many studies inferred that omalizumab is ben-
eficial in CSU with a likely autoimmune etiology,25 other 
studies have demonstrated the efficacy of omalizumab in 
CSU irrespective of autoimmune status; in fact, a prospec-
tive study showed that omalizumab is an effective treatment 
for CSU patients with negative autoantibody assays against 
either IgE or its high-affinity receptor, who are resistant to 
antihistamines.5
The first study that investigated optimal dosing of omali-
zumab in CU was a Phase II trial conducted by Saini et al 
in 2011 (ClinicalTrials.gov identifier: NCT00866788). This 
was a dose-ranging study named MYSTIQUE that assessed 
the efficacy of single-dose omalizumab 75 mg, 300 mg, and 
600 mg compared with placebo over 4 weeks (plus 12 weeks 
of follow-up) in 90 adolescents and adults (aged 12–75 years) 
with CSU unresponsive to approved dosages of H1 antihis-
tamines. The authors demonstrated that a single fixed dose 
of 300 mg or 600 mg of the drug (unlike in asthma where 
the dose is adjusted according to serum levels of IgE and 
patient weight) is a rapid and effective therapeutic option 
for patients who are symptomatic despite treatment with H1 
antihistamines.29
Later, the results of the three Phase III clinical trials have 
been reported. In the first trial, named ASTERIA II study 
(Clinicaltrials.gov identifier: NCT01292473),20 Maurer et al 
randomly assigned 323 patients (adults and adolescents 
aged .12 years) with persistent CSU despite treatment 
with H1 antihistamines at approved dose to receive 75 mg, 
150 mg, or 300 mg of omalizumab or placebo (three monthly 
subcutaneous [SC] injections during 12 weeks, followed by 
a 16-week follow-up period). The primary efficacy outcome 
of this study was the change from baseline in a weekly itch 
severity score (ISS) (this score ranges from 0 to 21, with 
higher scores indicating more severe itching). The baseline 
weekly ISS was approximately 14 in all four study groups. 
After the treatment, the mean (± standard deviation) change 
from baseline in the weekly ISS at week 12 was reduced 
to -8.1±6.4 in the 150 mg group (P=0.001) and to -9.8±6.0 
in the 300 mg group (P,0.001) without reaching statistical 
significance in the 75 mg group (-5.9±6.5, P=0.46) and in the 
placebo group (-5.1±5.6). The rate of adverse events (AEs) 
was low and similar across the groups, although it was higher 
in the 300 mg group (6%) than in the placebo group (3%) or 
in either the 75 mg or the 150 mg group (1% for each).20
The second one is the study named GLACIAL (Clinical-
trials.gov identifier: NCT01264939).18 In this study, Kaplan 
et al evaluated the safety and efficacy of 24 weeks of treat-
ment with omalizumab in 336 patients aged 12–75 years 
(18–75 years in Germany) with persistent CSU despite treat-
ment with H1 antihistamines at up to four times the approved 
dose plus H2 antihistamines, leukotriene receptor antagonists, 
or both. In this study, the 336 patients were randomized to 
receive six SC injections at 4-week intervals of either 300 mg 
of omalizumab or placebo, followed by a 16-week observation 
period. The primary objective of the study was to evaluate the 
overall safety of omalizumab compared with placebo. Effi-
cacy was evaluated at weeks 12 and 24 and includes scores for 
itch severity, wheals, and urticaria activity. The overall inci-
dence and severity of AEs were similar between omalizumab 
and placebo recipients. At week 12, the mean change from 
baseline in weekly ISS was 28.6 (95% confidence interval, 
29.3–27.8) in the omalizumab group compared with 24.0 
(95% confidence interval, 25.3–22.7) in the placebo group 
(P,0.001). Significant improvements were seen in additional 
efficacy end points at week 12; these benefits were sustained 
to week 24. Side effects were more likely to be reported in 
patients treated with the highest dose.
The last published study was named ASTERIA I 
(ClinicalTrials.gov identifier: NCT01287117).19 In this study, 
319 patients aged 12–75 years with CSU who remained 
symptomatic despite treatment with approved doses of H1 
antihistamines were randomized to receive SC placebo or 
omalizumab 75 mg, 150 mg, or 300 mg every 4 weeks for 
24 weeks followed by 16 weeks of follow-up. The primary 
end point was change from baseline in weekly ISS at week 12. 
Efficacy results in ASTERIA I were similar to those from the 
other Phase III studies: ASTERIA II and GLACIAL.
The summary of all Phase III studies is that omalizumab 
significantly reduced symptoms in patients with CSU refrac-
tory to H1 antihistamines. Median time to response was 
shortest in the omalizumab 300 mg group and suggests a 
relationship between omalizumab dose and time to onset. 
In these studies, there were no new safety concerns relative 
to the known tolerability profile of omalizumab derived from 
its use in treating allergic asthma. There were no anaphylactic 
reactions or clinically relevant changes in laboratory param-
eters. There were no anti-omalizumab antibodies detected at 
week 40 in the GLACIAL trial.
We have also collected data on the efficacy and safety 
of omalizumab in 110 patients from nine Spanish hospitals 





suffering from refractory CSU to available treatments in 
real-life practice, and the results are similar, even better 
than previously reported in controlled trials. Ninety (81.8%) 
patients exhibited a complete or significant response, 
12 (10.9%) had partial response, and eight (7.2%) showed 
no response. Sixty-six (60%) patients were able to stop all 
concomitant medications, remaining asymptomatic treated 
with omalizumab alone. No serious AEs were reported. We 
did not find differences when we compared efficacy and time 
of response among different doses or scheduled protocols, 
even considering the different types of CSU included in 
the analysis and subanalysis (CSU with or without associ-
ated physical urticaria, CSU with angioedema, and chronic 
autoimmune urticaria patients). Of the 110 patients included, 
41 discontinued use of omalizumab, 21 remained free of 
symptoms, and 20 required a reintroduction of the treatment. 
It is interesting to note that, in our series, omalizumab did 
not lose effectiveness upon reintroduction, and was equally 
effective again in 18 of the 20 patients in whom the drug 
was withdrawn.30 This effectiveness after reintroduction 




Omalizumab is a recombinant DNA-derived humanized 
monoclonal antibody produced in Chinese hamster ovary 
cells that selectively binds to human IgE. Xolair is a sterile, 
white, preservative-free lyophilized powder that is recon-
stituted with water for injections and administered as an 
SC injection. Prefilled syringe of 0.5 mL contains 75 mg of 
omalizumab, and prefilled syringe of 1 mL contains 150 mg 
of omalizumab. The solution for injection in prefilled syringe 
contains l-arginine hydrochloride, l-histidine hydrochloride, 
l-histidine, polysorbate 20, and water for injection as solvents. 
The average absolute bioavailability of omalizumab after 
SC administration is 62%. Peak serum concentrations are 
obtained on average 6–8 days after SC administration of a 
single dose. The pharmacokinetics of omalizumab is linear 
at doses (0.5 mg/kg). The apparent volume of distribution is 
78 mL/kg. Maximal suppression of free IgE in serum occurs 
3 days after SC administration of omalizumab, and IgE levels 
remain suppressed throughout treatment with omalizumab 
administered every 4 weeks. Omalizumab is eliminated via 
the same processes as endogenous IgG, as well as via specific 
binding and complex formation with IgE. IgG is habitually 
eliminated by the liver, principally by intracellular degradation 
following endocytosis (eg, by cells of the reticule endothelial 
system). Intact IgG is also eliminated in the bile. The terminal 
elimination half-life of omalizumab was estimated by popu-
lation pharmacokinetic simulations to be 24 days at stable 
equilibrium, and the apparent clearance was 3 mL/kg/day 
for a patient with an average weight of 80 kg. Population 
pharmacokinetic modeling suggests that, in the treatment of 
patients with CSU, there is no need for dosage adjustment 
based on age, race/ethnicity, sex, body weight, baseline IgE 
levels, autoantibodies to FcεRI, or concomitant therapy with 
H2 antihistamines or leukotriene receptor antagonists. The 
pharmacokinetics of omalizumab has not been studied in CSU 
patients with renal or hepatic alterations.32
Mechanism of action of omalizumab 
in CSU
The mechanism of action of omalizumab in CSU has not yet 
been elucidated. Interestingly, the mechanism of omalizumab 
appears to be different in CU and allergic asthma, for which 
the drug has been previously approved. In CU, dosage is 
not dependent on serum IgE levels, and response is seen 
in a subset of CSU patients, quickly after only 12 hours. 
Omalizumab is likely to achieve its therapeutic effects in 
urticaria through diverse mechanisms. Omalizumab results 
in a significant and rapid reduction in serum levels of free 
IgE, with subsequent and late downregulation of FcεRI (IgE 
high-affinity receptor) and FcεRII (IgE low-affinity receptor), 
as well as possible abduction of incoming allergen molecules 
and IgE immune complexes, which may abolish the abil-
ity of IgE to potentiate mast cell activity in this way. This 
may lead to nonspecific desensitization of mast cells and/or 
basophils in the skin, and thus explain the rapid therapeutic 
response seen in clinical practice.33 In addition, omalizumab 
has been shown to downregulate not only IgE receptors on 
effector cells, including mast cells and basophils, but also 
dendritic cells.34 The latter effect suggests that blocking 
IgE can inhibit more chronic aspects of allergic inflamma-
tion involving T-cell activation. Moreover, omalizumab is 
thought to mediate some of its anti-inflammatory action by 
inducing apoptosis of eosinophils.35
Clearly though, the precise mechanisms by which omali-
zumab acts require further investigation.
Omalizumab in pregnant women 
and nursing infants
Omalizumab has been recently assigned to pregnancy cat-
egory B by the FDA. Animal studies have failed to reveal 
evidence of maternal toxicity, embryotoxicity, or teratoge-
nicity. There are no controlled data in human pregnancy. 





Recently, the Xolair Pregnancy Registry (EXPECT) has 
been published,36 in which 188 of 191 pregnant women 
were exposed to omalizumab (indicated by asthma) dur-
ing their first trimester, with no apparent increased birth 
prevalence or patterns of major anomalies. Ninety-eight 
infants were also exposed to omalizumab while breast-
feeding, with a median omalizumab exposure duration of 
3.9 months without incidences. There are only few cases 
of use of omalizumab in CU pregnant women reported;37,38 
efficacy seems similar to that of the rest of CU patients 
(unpublished observations). Nevertheless, omalizumab is 
only recommended for use during pregnancy when potential 
benefit outweighs risk.
There are no data on the excretion of omalizumab into 
human milk. Animal studies realized by Genentech with 
cynomolgus monkeys have demonstrated milk levels that 
were 1.5% of maternal blood levels. IgG is excreted into 
human milk, and it is expected that omalizumab is also 
excreted. The effects in the nursing infant are unknown. 
The manufacturer (Genentech) recommends that caution be 
used when administering omalizumab to nursing women.
Omalizumab in children with CSU
There is very little published information on children 
suffering from CSU.39 To date, omalizumab has not been 
studied in children suffering from CSU aged ,12 years. 
Accordingly, most of the recommendations contained in 
the current guidelines1–3 for the prevention and treatment of 
CSU in children are based on extrapolation of data obtained 
in Phase III clinical studies that included only adults and 
children above 12 years of age.18–20 The FDA and the EMA 
have approved omalizumab for the treatment of CSU 
only in children aged 12 years and above refractory to H1 
antihistamines.16,17
Conclusion
Convincing evidence in support of the efficacy and safety of 
omalizumab in the treatment of CSU has accumulated over 
the past few years. Omalizumab has been shown to be an 
effective and well-tolerated add-on therapy in patients with 
CSU unresponsive to H1 antihistamines. There are several 
important questions regarding the use of omalizumab for the 
treatment of CSU that remain to be answered. Well-designed 
studies are needed to determine the patient profile most 
suitable for omalizumab treatment, the optimal duration of 
therapy, and rates of long-term remission. In addition, poten-
tial long-term side effects of omalizumab in the treatment of 
CSU require further investigation.
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